Tezspire (tezepelumab-ekko) Pre-filled Pen — Point32Health

severe asthma

Initial criteria

Diagnosis of severe asthma OR current treatment with an alternative biologic indicated for moderate to severe asthma
Patient age ≥ 12 years
Prescribed by or in consultation with an allergist, immunologist, or pulmonologist
History within the past 12 months of two or more asthma exacerbations requiring oral or injectable corticosteroid treatment OR one asthma exacerbation resulting in hospitalization
Patient currently maintained on a maximally tolerated inhaled corticosteroid plus at least one other asthma maintenance medication (e.g., long-acting inhaled beta2-agonist, long-acting muscarinic antagonist, leukotriene receptor antagonist)
Patient will not be concurrently treated with an alternative biologic for asthma

Documented diagnosis of severe asthma
Patient age ≥ 12 years
Prescribed by or in consultation with an allergist, immunologist, or pulmonologist
Patient experienced a therapeutic response as defined by one of the following: increase in percent predicted FEV1 from pretreatment baseline, reduction in dose of inhaled corticosteroids required to control asthma, reduction in asthma exacerbations (e.g., decreased frequency of unscheduled emergency department/urgent care visits), reduction in asthma symptoms (e.g., chest tightness, coughing, shortness of breath, nocturnal awakenings), or reduction in the use of oral corticosteroids to treat and/or prevent asthma exacerbations
Patient will not be concurrently treated with an alternative biologic for asthma

initial 6 months, reauth 12 months